Vanguard Global Advisers’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
Other funds holding FATE
Vanguard Global Advisers's FATE Position: Q3 2026 in Review
Vanguard Global Advisers reduced its Fate Therapeutics (FATE) stake by 52% in Q3 2026, selling an estimated $124K and leaving 43,754 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #2754.
Vanguard Global Advisers first reported a position in FATE in Q1 2026 and has held it in 3 quarters since. The position peaked at $248K in Q2 2026. 142 funds tracked by Wall St. Rank hold FATE as of Q3 2026.
- Vanguard Global Advisers held 43,754 shares of Fate Therapeutics worth $104K as of Q3 2026.
- Vanguard Global Advisers sold 47,957 Fate Therapeutics shares in Q3 2026, an estimated $124K.
- Fate Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2754 holding.
- Vanguard Global Advisers first reported a position in Fate Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Fate Therapeutics position peaked at $248K in Q2 2026.
- 142 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.